cortexolone 17α,21-dipropionate | 19608-30-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: cortexolone 17α,21-dipropionate
• 英文别名: [2-[(8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3-oxo-17-propanoyloxy-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate
• CAS: 19608-30-1
• 化学式: C₂₇H₃₈O₆
• 分子量: 458.595
• InChiKey: FAZSVJOMLJRPMK-XYZFIOBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  86.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  cortexolone 17α,21-dipropionate 以99的产率得到21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮
  参考文献：
  名称：

  [EN] 17ALFA, 21-DIHYDROXYPREGNENE ESTERS AS ANTIANDROGENIC AGENTS
  [FR] ESTERS DE 17ALFA, 21-DIHYDROXYPREGNENE UTILISES COMME AGENTS ANTIANDROGENES

  摘要：

  17α,21-二羟基孕酮-4,9-二烯-3,20-二酮和17α,21-二羟基孕酮-4-烯-3,20-二酮17和/或21酯具有显著的抗雄激素活性，并且还提供了制备这些化合物的方法。

  公开号：

  WO2003014141A1
• 作为产物：
  描述：

  脱氧可的松 、 丙酸酐 在 对甲苯磺酸 作用下， 以 丙酸 为溶剂， 生成 cortexolone 17α,21-dipropionate
  参考文献：
  名称：

  Lipase-catalyzed preparation of corticosteroid 17α-esters endowed with antiandrogenic activity

  摘要：

  Several 17 alpha-monoesters of cortexolone and its Delta(9)-derivative are endowed with antiandrogenic activity. Their synthesis can be accomplished by means of a lipase-catalyzed chemoselective alcoholysis of the corresponding 17 alpha,21-diesters. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2008.05.086

文献信息

• ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES
  申请人：Ajani Mauro

  公开号：US20110092472A1

  公开（公告）日：2011-04-21

  The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone 17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.

  本发明涉及一种新的酶法工艺，用于从相应的17α,21-二酯出发获得皮质酮17α-单酯和/或其9,11-去氢衍生物的工艺，其中包括酶催化的醇解反应。此外，本发明涉及皮质酮17α-丙酸酯和9,11-去氢皮质酮17α-丁酸酯的新晶体形式。
• Cortexolone-17alpha-propionate in crystalline form I
  申请人：Cosmo S.p.A.

  公开号：EP2503004A1

  公开（公告）日：2012-09-26

  The present invention refers to a new enzymatic process for obtaining cortexolone 17α-propionate starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to a new crystalline form of cortexolone 17α-propionate.

  本发明是指一种从相应的 17α，21-二酯开始获得可的松 17α-丙酸酯的酶法新工艺，该工艺包括酶醇解反应。 此外，本发明还涉及一种新的可的松 17α 丙酸酯结晶形式。
• Cortexolone-17alpha-propionate in cristalline hydrate form IV
  申请人：Cosmo S.p.A.

  公开号：EP2503005A2

  公开（公告）日：2012-09-26

  The present invention refers to a new enzymatic process for obtaining cortexolone-17α-propionate starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to a new crystalline form of cortexolone 17α-propionate.

  本发明是指一种从相应的 17α，21-二酯开始获得可的松酮-17α-丙酸酯的酶法新工艺，该工艺包括酶醇解反应。 此外，本发明还涉及一种新的可的松酮-17α-丙酸酯结晶形式。
• PHARMACEUTICAL COMPOSITIONS CONTAINING CORTEXOLONE-17-ALPHA-PROPIONATE
  申请人：Cassiopea S.p.A.

  公开号：EP2966175A1

  公开（公告）日：2016-01-13

  The present invention refers to pharmaceutical compositions containing new crystalline forms of cortexolone 17α-propionate. These compositions are useful for the treatment of pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages.

  本发明是指含有 17α 丙酸可的松新结晶形式的药物组合物。这些组合物可用于治疗影响泌尿生殖系统、内分泌系统、皮肤和/或皮肤附属物的病症。
• CORTEXOLONE-17-ALPHA-PROPIONATE CRYSTALLINE FORM III AND ITS PHARMACEUTICAL USE
  申请人：Cassiopea S.p.A.

  公开号：EP3521298A1

  公开（公告）日：2019-08-07

  The present invention refers to new crystalline forms of cortexolone 17α-propionate and their pharmaceutical use.

  本发明涉及可的松 17α 丙酸酯的新结晶形式及其制药用途。